Quotient BioResearch was founded in 2007 by Paul Cowan, the former Chief Financial Officer of Inveresk Research Group, Inc. Cowan left Inveresk Research in 2004 following its sale to Charles River Laboratories for approximately $1.5 billion. The principal investors in Quotient BioResearch are Paul Cowan, property companies Helical Bar plc and Dencora Estates, and the Group’s management and employees.

Quotient BioResearch is focused on building a global group providing high value-added analytical and safety evaluation services and products for the bioscience industries, including sport for which it has, through HFL, internationally respected expertise.

The strategic plan of Quotient BioResearch is to grow through acquisition, investment and recruitment. In 2007, Quotient BioResearch acquired:

• HFL, a leading European provider of drug surveillance testing services for sport and bioanalytical and biomarker testing services to the pharmaceutical and biotechnology sectors;
• Alba Bioscience, a leading provider of diagnostic reagents, principally for blood typing; and
• GR Micro, a leading provider of microbiology and molecular biology services to the global pharmaceutical and biotechnology sectors.

In February 2008, Quotient acquired BioDynamics, a provider of metabolism, bioanalytical and radiochemistry services.

The Quotient group of companies employs around 350 people in the UK and operates from sites in Cambridgeshire, Northamptonshire, London and Edinburgh.

For further information on each of the Quotient BioResearch Group companies, please click on their logo below.